SLBT
SL Science Holding Limited
stock NASDAQ

SL Bio completed its SPAC merger with Horizon Space Acquisition II Corp. in June, and the combined company now trades on Nasdaq under the ticker SLBT.
I’m not very familiar with biotech SPACs, especially after the merger is already completed.
For this kind of company, what would you usually check first?
Clinical progress? cash position? dilution risk? management team? or whether the business can actually become commercial?
Just wondering how people evaluate these deals.
Source:
https://www.globenewswire.com/news-release/2026/06/12/3311284/0/en/sl-bio-ltd-and-horizon-space-acquisition-ii-announce-closing-of-business-combination-and-listing-on-the-nasdaq-global-market.html

SL Bio completed its SPAC merger with Horizon Space Acquisition II Corp. in June, and the combined company now trades on Nasdaq under the ticker SLBT.
I’m not very familiar with biotech SPACs, especially after the merger is already completed.
For this kind of company, what would you usually check first?
Clinical progress? cash position? dilution risk? management team? or whether the business can actually become commercial?
Just wondering how people evaluate these deals.
Source:
https://www.globenewswire.com/news-release/2026/06/12/3311284/0/en/sl-bio-ltd-and-horizon-space-acquisition-ii-announce-closing-of-business-combination-and-listing-on-the-nasdaq-global-market.html